(OSUR) OraSure Technologies - NASDAQ
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 288m USD | Total Return: 45.1% in 12m
Avg Turnover: 3.24M
Qual. Beats: -1
Rev. Trend: -99.0%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -351.1 is critical
Tailwinds
Tailwind
OraSure Technologies (OSUR) specializes in the development and distribution of point-of-care diagnostic tests and specimen collection devices. Its portfolio spans infectious disease testing for HIV, HCV, and COVID-19, alongside genomic and microbiome collection tools under brands such as Oragene and OMNIgene. The company serves a diverse client base including clinical laboratories, government agencies, and pharmaceutical firms.
Operating within the Health Care Supplies sub-industry, OraSure utilizes a business model focused on decentralized testing, which reduces the need for traditional laboratory infrastructure. This sector is characterized by high regulatory barriers, as products often require FDA clearance or CE marking before commercialization. The companys expansion into molecular self-tests for STIs reflects a broader industry shift toward at-home diagnostic solutions.
Investors looking for a deeper breakdown of these fundamentals should consult ValueRay for further analysis. Founded in 1987 and based in Pennsylvania, OraSure maintains a global footprint with sales operations across North America, Europe, and Africa.
- Diagnostic segment margins expand as InteliSwab COVID-19 volume stabilizes
- Molecular collection revenue grows via genomics and microbiome market expansion
- Operating expense reductions and restructuring drive positive free cash flow
- New product pipeline targets large-scale infectious disease and STI testing markets
| Net Income: -75.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.13 > 0.02 and ΔFCF/TA -12.25 > 1.0 |
| NWC/Revenue: 174.0% < 20% (prev 178.4%; Δ -4.37% < -1%) |
| CFO/TA -0.11 > 3% & CFO -43.2m > Net Income -75.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.7m) vs 12m ago -6.93% < -2% |
| Gross Margin: 41.02% > 18% (prev 42.54%; Δ -1.53% > 0.5%) |
| Asset Turnover: 27.01% > 50% (prev 35.32%; Δ -8.31% > 0%) |
| Interest Coverage Ratio: -351.1 > 6 (EBIT TTM -73.0m / Interest Expense TTM 208k) |
| A: 0.52 (Total Current Assets 240.8m - Total Current Liabilities 44.1m) / Total Assets 379.2m |
| B: -0.51 (Retained Earnings -194.5m / Total Assets 379.2m) |
| C: -0.17 (EBIT TTM -73.0m / Avg Total Assets 418.4m) |
| D: 4.76 (Book Value of Equity 313.3m / Total Liabilities 65.8m) |
| Altman-Z'' = 5.55 = AAA |
| DSRI: 1.76 (Receivables 26.4m/21.5m, Revenue 113.0m/161.6m) |
| GMI: 1.04 (GM 42.54% / 41.02%) |
| AQI: 1.22 (AQ_t 0.23 / AQ_t-1 0.19) |
| SGI: 0.70 (Revenue 113.0m / 161.6m) |
| TATA: -0.08 (NI -75.1m - CFO -43.2m) / TA 379.2m) |
| Beneish M = -2.46 (Cap -4..+1) = BBB |
As of June 15, 2026, the stock is trading at USD 4.18 with a total of 505,182 shares traded.
Over the past week, the price has changed by +3.47%,
over one month by +41.69%,
over three months by +33.55% and
over the past year by +45.14%.
OraSure Technologies has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold OSUR.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.8 | 13.6% |
P/E Forward = 40.0
P/S = 2.5525
P/B = 0.8855
P/EG = 6.19
Revenue TTM = 113.0m USD
EBIT TTM = -73.0m USD
EBITDA TTM = -63.5m USD
Long Term Debt = 19.5m USD (estimated: total debt 40.5m - short term 21.0m)
Short Term Debt = 21.0m USD (from shortTermDebt, last quarter)
Debt = 53.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.7m
Net Debt = -123.8m USD (calculated: Debt 53.1m - CCE 177.0m)
Enterprise Value = 164.6m USD (288.5m + Debt 53.1m - CCE 177.0m)
Interest Coverage Ratio = -351.1 (Ebit TTM -73.0m / Interest Expense TTM 208k)
EV/FCF = -3.44x (Enterprise Value 164.6m / FCF TTM -47.9m)
FCF Yield = -29.08% (FCF TTM -47.9m / Enterprise Value 164.6m)
FCF Margin = -42.36% (FCF TTM -47.9m / Revenue TTM 113.0m)
Net Margin = -66.42% (Net Income TTM -75.1m / Revenue TTM 113.0m)
Gross Margin = 41.02% ((Revenue TTM 113.0m - Cost of Revenue TTM 66.7m) / Revenue TTM)
Gross Margin QoQ = 37.44% (prev 40.98%)
Tobins Q-Ratio = 0.43 (Enterprise Value 164.6m / Total Assets 379.2m)
Interest Expense / Debt = 0.39% (Interest Expense 208k / Debt 53.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -57.7m (EBIT -73.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.46 (Total Current Assets 240.8m / Total Current Liabilities 44.1m)
Debt / Equity = 0.17 (Debt 53.1m / totalStockholderEquity, last quarter 313.3m)
Debt / EBITDA = 1.95 (negative EBITDA) (Net Debt -123.8m / EBITDA -63.5m)
Debt / FCF = 2.59 (negative FCF - burning cash) (Net Debt -123.8m / FCF TTM -47.9m)
Total Stockholder Equity = 349.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.94% (Net Income -75.1m / Total Assets 379.2m)
RoE = -21.50% (Net Income TTM -75.1m / Total Stockholder Equity 349.2m)
RoCE = -19.81% (EBIT -73.0m / Capital Employed (Equity 349.2m + L.T.Debt 19.5m))
RoIC = -16.46% (negative operating profit) (NOPAT -57.7m / Invested Capital 350.4m)
WACC = 7.07% (E(288.5m)/V(341.6m) * Re(8.31%) + D(53.1m)/V(341.6m) * Rd(0.39%) * (1-Tc(0.21)))
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -46.67 | Cagr: -3.23%
[DCF] Fair Price = unknown (Cash Flow -47.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.93 | # QB: -1
Revenue Correlation: -98.97 | Revenue CAGR: -44.53% | SUE: 0.16 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.18 | Chg30d=-26.63% | Revisions=-33% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.15 | Chg30d=-7.49% | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.70 | Chg30d=-24.70% | Revisions=-33% | GrowthEPS=-1.3% | GrowthRev=+4.1%
EPS next Year (2027-12-31): EPS=-0.50 | Chg30d=-7.09% | Revisions=-33% | GrowthEPS=+28.0% | GrowthRev=+6.8%
[Analyst] Revisions Ratio: -33%